TENX Overview

Price Target Update: The average one-year price target for Tenax Therapeutics (NasdaqCM:TENX) has been revised to $25.76 per share, reflecting a 12.22% increase from the previous estimate of $22.95, with a potential range between $20.20 and $31.50 per share.

Fund Sentiment: There are currently 48 funds reporting positions in Tenax Therapeutics, marking a 20% increase in ownership over the last quarter, with total shares owned by institutions rising by 109.94% to 4,753K shares.

Significant Shareholder Activity: Ikarian Capital and Boothbay Fund Management both increased their holdings by 100%, while VR Adviser raised its stake by 77.48%, indicating strong interest from institutional investors.

Fintel Overview: Fintel provides comprehensive investment research tools, including fundamentals, analyst reports, and ownership data, aimed at individual investors and small hedge funds to enhance their trading strategies.

Company Performance: Tenax Therapeutics Inc. reported a loss of $15.8 million in its third quarter, equating to a loss of 40 cents per share.

Market Expectations: The reported loss was better than Wall Street expectations, which anticipated a loss of $1.33 per share according to analysts surveyed by Zacks Investment Research.

Financial Performance: Tenax Therapeutics Inc. reported a loss of $10.8 million in its second quarter, equating to 27 cents per share.

Market Expectations: The company's results exceeded Wall Street expectations, which anticipated a larger loss of 50 cents per share according to analysts from Zacks Investment Research.

Prospectus Filing: Tenax Therapeutics filed a prospectus for the resale of up to 378,346 shares of common stock and approximately 3.76 million shares issuable from pre-funded warrants, with no proceeds going to the company from this sale.

Recent Financial Activity: The company recently announced a $25 million private placement and has available historical earnings data and financial information.